Synthetic cannabinoid compounds for treatment of pain and anxiety
Synthetic cannabinoid compounds for treatment of pain and anxiety by administering to an individual in need thereof a pharmaceutical composition including a compound having the structure: or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable vehicle therefor.
1. A method of treating pain comprising administering to an individual in need thereof a pharmaceutical composition comprising a compound having the structure:
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable vehicle therefor.
2. The method of claim 1 , wherein the pharmaceutical composition contains a racemic mixture of enantiomers having the structures:
3. The method of claim 1 , wherein the pharmaceutical composition contains at least about 99% enantiomeric purity, having the structure:
4. The method of claim 1 , wherein the pharmaceutically acceptable vehicle is a capsule, tablet, syrup, lozenge, inhaler, e-cigarette, chewable gum, nasal spray, transdermal patch, liquid, transmucosal vehicle, hydrogel, nanosome, liposome, noisome, nanoparticle, nanosphere, microsphere, microparticle, microemulsion, nanosuspension, or micelle.
5. The method of claim 1 , wherein the pain is neuropathic pain due to multiple sclerosis, pain due to damage of the brachial plexus and HIV infection, pain in rheumatoid arthritis, cancer pain, headache, menstrual pain, pain due to spinal cord injury, pain due to chronic bowel inflammation, or pain due to neuralgias.
6. The method of claim 1 , wherein the pain is due to diseases with nausea and anorexia.
7. A method of treating anxiety comprising administering to an individual in need thereof a pharmaceutical composition comprising a compound having the structure:
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable vehicle therefor.
8. The method of claim 7 , wherein the pharmaceutical composition contains a racemic mixture of enantiomers having the structures:
9. The method of claim 7 , wherein the pharmaceutical composition contains at least about 99% enantiomeric purity, having the structure:
10. The method of claim 7 , wherein the pharmaceutically acceptable vehicle is a capsule, tablet, syrup, lozenge, inhaler, e-cigarette, chewable gum, nasal spray, transdermal patch, liquid, transmucosal vehicle, hydrogel, nanosome, liposome, noisome, nanoparticle, nanosphere, microsphere, microparticle, microemulsion, nanosuspension, or micelle.
11. The method of claim 7 , wherein the anxiety is associated with substance use disorders, post-traumatic stress disorder, general anxiety disorder, panic disorder, social anxiety disorder, or obsessive-compulsive disorder.